

## Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia

U. Vivian Ukah, Beth Payne, Jennifer A. Hutcheon, J. Mark Ansermino, Wessel Ganzevoort, Shakila Thangaratnam, Laura A. Magee, Peter von Dadelszen

See Editorial Commentary, pp 569–571

**Abstract**—Early-onset preeclampsia is associated with severe maternal and perinatal complications. The fullPIERS model (Preeclampsia Integrated Estimate of Risk) showed both internal and external validities for predicting adverse maternal outcomes within 48 hours for women admitted with preeclampsia at any gestational age. This ability to recognize women at the highest risk of complications earlier could aid in preventing these adverse outcomes through improved management. Because the majority ( $\approx 70\%$ ) of the women in the model development had late-onset preeclampsia, we assessed the performance of the fullPIERS model in women with early-onset preeclampsia to determine whether it will be useful in this subgroup of women with preeclampsia. Three cohorts of women admitted with early-onset preeclampsia between 2012 and 2016, from tertiary hospitals in Canada, the Netherlands, and United Kingdom, were used. Using the published model equation, the probability of experiencing an adverse maternal outcome was calculated for each woman, and model performance was evaluated based on discrimination, calibration, and stratification. The total data set included 1388 women, with an adverse maternal outcome rate of 7.3% within 48 hours of admission. The model had good discrimination, with an area under the receiver operating characteristic curve of 0.80 (95% confidence interval, 0.75–0.86), and a calibration slope of 0.68. The estimated likelihood ratio at the predicted probability of  $\geq 30\%$  was 23.4 (95% confidence interval, 14.83–36.79), suggesting a strong evidence to rule in adverse maternal outcomes. The fullPIERS model will aid in identifying women admitted with early-onset preeclampsia in similar settings who are at the highest risk of adverse outcomes, thereby allowing timely and effective interventions. (*Hypertension*. 2018;71:659-665. DOI: 10.1161/HYPERTENSIONAHA.117.10318.) • [Online Data Supplement](#)

**Key Words:** calibration ■ gestational age ■ preeclampsia ■ pregnancy ■ prognosis

Preeclampsia affects up to 5% of pregnancies worldwide and contributes substantially to maternal and fetal morbidity and mortality.<sup>1,2</sup> Maternal complications that could arise from preeclampsia include placental abruption and acute renal failure while fetal complications include small-for-gestational age babies, respiratory distress, and stillbirth.<sup>3,4</sup> Preeclampsia can be classified as early-onset preeclampsia, that is, preeclampsia occurring before 34 weeks of gestation, or as late-onset preeclampsia occurring from 34 weeks onwards. Although the pathogenesis of preeclampsia is not fully understood, studies have suggested that the causes of these 2 types of preeclampsia may be different.<sup>5,6</sup> It has been proposed that early-onset preeclampsia is as a result of shallow invasion of the maternal spiral arteries by the trophoblasts resulting in impaired

remodeling of the arteries (placental preeclampsia) while late-onset preeclampsia is associated with maternal predisposition to arterial disease resulting in a hyperinflammatory state during pregnancy (maternal preeclampsia).<sup>5,7</sup> Although late-onset preeclampsia is more common, early-onset preeclampsia is associated with more severe outcomes, such as fetal growth restriction.<sup>3</sup> The management of early-onset preeclampsia is complicated because delivery remains the only cure for preeclampsia and could result in early preterm birth with the concomitant severe consequences of prematurity.<sup>3,8,9</sup> Therefore, delaying delivery where possible would be preferable although the length of time for expectant management is unclear because the mother is also at increased risk of complications.<sup>1,8</sup> The ability to predict the risk of maternal complications for women

Received September 12, 2017; first decision September 30, 2017; revision accepted January 18, 2018.

From the Departments of Obstetrics and Gynaecology (U.V.U., J.A.H.) and Anesthesiology, Pharmacology, and Therapeutics (B.P., J.M.A.), University of British Columbia, Vancouver, Canada; Healthy Starts Theme, BC Children's Hospital Research Institute, Vancouver, Canada (U.V.U., B.P., J.A.H., J.M.A.); Departments of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, The Netherlands (W.G.); Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom (S.T.); and School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, United Kingdom (L.A.M., P.v.D.).

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.117.10318/-/DC1>.

Correspondence to U. Vivian Ukah, Department of Obstetrics and Gynaecology, University of British Columbia, 950 W 28th Ave, Vancouver, BC, V5Z 4H4, Canada. E-mail Vivian.Ukah@cw.bc.ca

© 2018 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.117.10318

admitted with early-onset preeclampsia would be highly beneficial to guide their management in care facilities.<sup>1,10</sup>

The fullPIERS model (Preeclampsia Integrated Estimate of Risk) was developed to predict severe maternal complications, including adverse central nervous system, cardiorespiratory and hematological outcomes (full list of outcomes in Table S1 in the [online-only Data Supplement](#)) from preeclampsia occurring within 48 hours of admission; this time frame was chosen to allow for clinical decisions, such as administration of corticosteroids, transfer to higher care units, and delivery. The model was developed using a prospective cohort of 2023 women admitted with preeclampsia in tertiary units in high-income countries and had a good excellent discriminatory ability with an area under the receiver operating curve (AUROC) of 0.88 (95% confidence interval [CI], 0.84–0.92).<sup>11</sup> The fullPIERS model was internally validated and also showed externally validity with AUROC of 0.82 (95% CI, 0.76–0.87). Although the majority of the cohort used for the model development was from women with late-onset preeclampsia, 31.4% of the women included in the study had early-onset preeclampsia.<sup>11</sup> A study assessing the model in a cohort of women with severe early-onset preeclampsia also showed an excellent discriminatory performance (AUROC, 0.97 [95% CI, 0.94–0.99]) although this study was underpowered to detect significant changes in model performance.<sup>12,13</sup> Therefore, our objective was to assess and confirm the validity of the fullPIERS model for early-onset preeclampsia, using a fully-powered, broad cohort of women admitted with early-onset preeclampsia in high-income countries, other than the one used in the development study.

## Methods

### Data, Analytic Methods (Code), and Research Materials Transparency

Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the ethics board of the University of British Columbia and the other organizations listed for the corresponding authors.

### Ethics

Ethical approval for this validation study was obtained from the Research Ethics Board of the University of British Columbia on March 1, 2014 (CREB#: H07-02207).

### Data Collection

Data used for this model assessment study were derived from 3 pre-existing cohorts of women admitted with early-onset preeclampsia in high-income countries. These were the (1) BCW hospital cohort (British Columbia Women), (2) the PETRA cohort (Preeclampsia Eclampsia Trial Amsterdam), and (3) the PREP cohort (Prediction of Complications in Early-Onset Preeclampsia).

The BCW cohort comprised data that were extracted from medical chart and electronic records of women admitted into the tertiary unit of the BCW hospital in Canada between January 2012 and May 2016. For this study, we restricted the BCW cohort to the women admitted with preeclampsia before 34 weeks of gestation. The PETRA cohort was made up of women recruited into the PETRA randomized trial study in the Netherlands between April 2000 and May 2003.<sup>14</sup> Data for the PETRA study were collected prospectively and only included women admitted with severe preeclampsia into tertiary centers between 24 and <34 weeks of gestation. The PREP cohort was made up of women recruited into the PREP study in the United Kingdom between December

2011 and April 2014.<sup>15</sup> Data for the PREP study were also collected prospectively and only included women admitted with preeclampsia into secondary and tertiary centers before 34 weeks of gestation. These cohorts were merged into a combined data set for our study with study marker retained to allow for separate study analysis.

### Definition of Preeclampsia and Adverse Outcomes

Preeclampsia was defined as hypertension and either proteinuria or hyperuricemia, or HELLP syndrome (hemolysis, elevated liver enzyme levels, and low platelet levels), as in the fullPIERS development study.<sup>11</sup> However, the PETRA cohort included only women if they had severe preeclampsia (diastolic blood pressure >110 mm Hg) HELLP syndrome<sup>14</sup> or gestational hypertension (diastolic blood pressure  $\geq$ 90 mm Hg with the absence of proteinuria) with fetal growth restriction (estimated fetal weight <10th centile).

The primary outcome used in our study was the same as in the model development study.<sup>11</sup> This was a composite outcome comprising of  $\geq$ 1 of the severe maternal complications listed in the [online-only Data Supplement](#) occurring within 48 hours of admission for preeclampsia (Table S1).

### Statistical Analyses

Using the worst measured predictor variables within 48 hours of admission measured before any outcome occurrence, the published fullPIERS model equation<sup>11</sup> (Equation 1) was applied to the combined data set to calculate the predicted probabilities of experiencing an adverse outcome for each woman.

The fullPIERS Logistic Regression Equation for the prediction of adverse maternal outcomes from preeclampsia:

$$\begin{aligned} -\logit(\pi) = & 2.68 + (-5.41 \times 10^{-2}; \text{gestational age at} \\ & \text{eligibility}) + 1.23(\text{chest pain or dyspnoea}) \\ & + (-2.71 \times 10^{-2}; \text{creatinine}) + (2.07 \times 10^{-1}; \text{platelets}) \\ & + (4.00 \times 10^{-5}; \text{platelets}^2) + (1.01 \times 10^{-2}; \text{aspartate} \\ & \text{trans aminase}) + (-3.05 \times 10^{-6}; \text{aspartate} \\ & \text{aminotransferase}^2) + (2.50 \times 10^{-4}; \text{creatinine} \\ & \times \text{platelet}) + (-6.99 \times 10^{-5}; \text{platelet} \times \text{aspartate} \\ & \text{transaminase}) + (-2.56 \times 10^{-3}; \text{platelet} \times \text{SpO}_2) \end{aligned} \quad (1)$$

The calculated probabilities were then used to assess the model performance for predicting adverse maternal outcomes within 48 hours of admission based on discrimination, calibration, and stratification and classification accuracy.<sup>16,17</sup>

Discriminative ability was interpreted as noninformative (area under the curve  $\leq$ 0.5), poor discrimination ( $0.5 <$  area under the curve  $<$ 0.7), or good discrimination (area under the curve  $\geq$ 0.7).<sup>18</sup> Before the merging of cohorts, the discriminative ability of the fullPIERS model was assessed in the individual cohorts.

Calibration was assessed by estimating the slope on a calibration plot of predicted versus observed outcome rates in each decile of predicted probability. Similar to the AUROC, calibration ability was interpreted as poor calibration (slope  $<$ 0.7), good calibration (slope  $0.7 \leq$  slope  $<$ 1.3).<sup>17</sup> The stratification capacity and classification accuracy of the model were assessed using a classification table with generated risk groups (based on categories established in the model development study). Stratification and classification ability were assessed based on the ability of the model to correctly classify the women into low- and high-risk categories.

Likelihood ratios were calculated for each group using the Deeks and Altman<sup>19</sup> method for a multcategory diagnostic test; the true- and false-positive rates, negative predictive values, and positive predictive values were also computed for each group.

### Missing Data

Multiple imputations by chained equations were used to generate plausible values for any missing variable except for missing  $\text{SpO}_2$  values that were imputed with 97%, similarly done in the fullPIERS model development study and to ensure consistency.<sup>11</sup> We used 10 iterations of multiple imputation to generate 10 data sets. The predicted probabilities of experiencing an adverse outcome for each woman were calculated in each data set, and the final predicted risks were combined by averaging the predicted probabilities for each

individual. The final average-predicted probabilities were used to evaluate the performance of the model for the imputation results.

**Sensitivity Analyses**

For secondary analyses, we evaluated the discriminatory performance of the model for predicting adverse outcomes within 7 days of admission. Because of known differences in the study design and definition of preeclampsia in the PETRA cohort<sup>14</sup> compared with the BCW and PREP cohorts, we conducted a sensitivity analysis evaluating the discriminatory performance of the model in the combined cohort excluding the PETRA cohort.

Recalibration of the model was also performed to account for differences between the development and validation cohort (early-onset preeclampsia).

All statistical analyses were performed using R version 3.1.3 (The R Project for Statistical Computing).

**Sample Size**

Our sample size was guided by simulation studies that recommend that validation studies should have at least 100 events (outcomes) to have 80% power at the 5% significance level.<sup>13,17</sup>

**Results**

**Cohort Description**

The BCW, PETRA, and PREP cohorts included 218, 216, and 954 women, respectively, making a total of 1388 women admitted with preeclampsia before 34 weeks of gestation in our analytic data set. The women in the BCW cohort appeared to be older and have a higher rate of chest pain or dyspnea and more interventions during pregnancy (higher administration of corticosteroids, antihypertensive medication, and magnesium sulfate; Table 1). The PETRA cohort had the highest reported rate of the HELLP syndrome and higher rates of stillbirth and neonatal death. The PREP cohort had higher multiparity and lower use of magnesium sulfate during pregnancy.

Compared with the fullPIERS development cohort, the early-onset cohorts reported more chest pain or dyspnea, higher administration of corticosteroid, shorter admission-to-delivery interval, and lower birth weights.

**Table 1. Maternal Characteristics for the Data Sets With Women GA <34 Years (BCW <34, Dutch PETRA, PREP)**

Characteristics	fullPIERS Cohort (Development; 2023 Women)	BCW (218 Women)	Dutch PETRA (216 Women)	PREP (954 Women)
<b>Demographics and pregnancy characteristics</b>				
HELLP syndrome	125 (6.2%)	27 (12.4%)	93 (43%)	10 (1.0%)*
Maternal age at EDD, y	31 (27, 36)	35 (30, 39)	30 (27, 34)	30 (26, 35)
Parity ≥1	581 (28.7%)	84 (31.2%)	65 (30.1%)	403 (42.2%)
Gestational age at eligibility, wk†	36 (33, 38.3)	31.0 (28.4, 32.7)	30.0 (27.4, 31.4)	31.4 (28.7, 32.7)
Multiple pregnancy	192 (9.5%)	40 (18.4%)	...	84 (8.8%)
Smoking in this pregnancy	249 (12.3%)	24 (11.1%)	...	87 (9.1%)
<b>Clinical measures</b>				
Systolic BP, mm Hg	160 (150, 176)	161 (150, 173)	160 (145, 170)	155 (145, 169)
Diastolic BP, mm Hg	102 (97.8, 110)	100 (94, 106)	105 (95, 110)	99 (92, 105)
Chest pain/dyspnoea†	90 (4.4%)	27 (12.4%)	15 (6.9%)	60 (6.3%)
Lowest platelet count (×10 <sup>3</sup> per L) †	192 [150, 241.5)	189 (133, 235)	164 (89, 227)	222 (176, 273)
Highest AST/ALT, U/L†	28 (21, 41)	37 (27, 65)	32 (24, 46)	18 (13, 28)
Creatinine	67 (58, 77)	64 (56, 78)	69 (58, 79)	59 (50, 69)
<b>Interventions during admission</b>				
Corticosteroids	550 (27.2%)	195 (89.5%)	153 (70.8%)	783 (82.1%)
Antihypertensive therapy	1381 (68.3%)	197 (90.4%)	171 (79.2%)	753 (78.9%)
MgSO <sub>4</sub>	690 (34.1%)	167 (76.6%)	89 (41.2%)	144 (15.1%)
<b>Pregnancy outcomes</b>				
Admission-to-delivery interval, d	2 (1, 5)	3 (1, 8)	8 (4, 15)	9 (3, 23)
Gestational age at delivery, wk	36.9 (34.1, 38.6)	32.0 (29.3, 33.6)	31.4 (28.3, 33.0)	33.1 (31.0, 34.9)
Birth weight	2141 (1441, 2807)	1340 (895, 1785)	1203 (839, 1506)	1625 (1260, 2165)
Stillbirth	20 (1.0%)	6 (2.8%)	20 (9.3%)	16 (1.7%)
Neonatal death	20 (1.0%)	3 (1.4%)	18 (8.3%)	23 (2.4%)

ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; BCW, British Columbia Women; BP, blood pressure; EDD, estimated date of delivery; fullPIERS, Preeclampsia Integrated Estimate of Risk; GA, gestational age; HELLP, hemolysis, elevated liver enzyme levels, and low platelet levels; MgSO<sub>4</sub>, magnesium sulfate; PETRA, Preeclampsia Eclampsia Trial Amsterdam; and PREP, Prediction of Complications in Early-Onset Preeclampsia.

\*Baseline rate only for HELLP syndrome in the PREP cohort.

†Variables included in the model.

The PETRA cohort also had the highest rate of adverse maternal outcomes within 48 hours of admission (14.8%) while the PREP cohort had the lowest rate (4.8%; Table 2). In total, the rate of adverse outcomes in the combined data set within 48 hours of admission was 7.3% (n=101), which was slightly higher than in the fullPIERS cohort with 5%.<sup>11</sup> The most commonly reported adverse outcomes within 48 hours of admission were low platelet count (n=26) and placental abruption (n=19); there was no reported case of maternal mortality (Table S2).

### Data Completeness and Imputation Analysis

After substituting missing Spo<sub>2</sub> values with 97% similar to the fullPIERS model development,<sup>11</sup> there were 43 (3.1%) cases of platelet, 46 (3.3%) cases of creatinine, and 77 (5.5%) cases of aspartate aminotransferase, missing within 48 hours of admission. There were no missing cases of gestational age at admission for preeclampsia, and none reported for chest pain or dyspnea.

Imputation of missing values did not seem to alter the model performance significantly; these results are presented in the model performance below.

### Model Performance

The women in the PETRA cohort had a higher median of calculated fullPIERS probability (Table 2) and AUROC (AUROC of 0.97 [95% CI, 0.94–0.99]). The model, combined data, showed a good discrimination with an AUROC of 0.80 (95% CI, 0.75–0.86; Figure 1) although the calibration was poor with a slope of 0.68 (95% CI, 0.56–0.79; Figure 2). Imputation of the combined data did not result in any change in discrimination (AUROC of 0.80 [95% CI, 0.75–0.85]) and calibration (0.63 [95% CI, 0.52–0.74]).

The stratification capacity in the early-onset preeclampsia cohort was good as with the model development study.<sup>11</sup> The fullPIERS model stratified the majority of the women (64%) into the low-risk groups (predicted probability of <2.5%) and 4.4% into the highest risk group (predicted probability of ≥30%; Table 3). Conversely, only ≈3% of women in the low-risk group of <2.5% had an adverse outcome while ≈55% of the women in the highest risk group experienced an adverse outcome. At the highest predicted probability group of ≥30%, the model had a likelihood ratio of 23.4 (95% CI, 14.8–36.8), showing strong evidence to rule in an adverse outcome; the

positive predictive values and negative predictive values were 96% and 65%, respectively. There was no predicted range showing strong evidence for ruling out adverse outcomes.

### Sensitivity Analyses

On secondary analyses, the fullPIERS model maintained a good discriminatory performance with AUROC of 0.74 (95% CI, 0.70–0.79) for predicting maternal adverse outcomes within 7 days of admission (Figure S1).

The performance of the model appeared to decrease after the exclusion of the PETRA cohort with AUROCs of 0.74 (95% CI, 0.67–0.81) and 0.70 (95% CI, 0.65–0.75) for predicting adverse maternal outcomes within 48 hours and 7 days of admission, respectively, although these were not significant as the CIs overlapped (Figure S2). Updating of the model intercept and slope resulted in improvement of the calibration performance (Figure S3) without affecting discriminatory performance. The updated model equation after model recalibration is shown in Equation 2.

Recalibrated fullPIERS Logistic Regression Equation for the prediction of adverse maternal outcomes from early-onset preeclampsia:

$$-\text{logit}(\pi) = -0.29 + (0.6777 \times \text{original fullPIERS model}) \quad (2)$$

## Discussion

### Main Findings


We assessed the fullPIERS model in women admitted with early-onset preeclampsia. The model maintained a good discriminatory and stratification performance within 48 hours; the model also performed well for predicting adverse outcomes occurring within 7 days. There was a marginal decrease in AUROC compared with the model performance in development (AUROC of 0.80 [95% CI, 0.75–0.86] in early-onset preeclampsia versus 0.88 [95% CI, 0.84–0.92] on development). The calibration performance of the model reduced in our cohort from an ideal slope of 1 to 0.68. Simple updating methods, such as recalibration of the intercept and slope, may be used to improve the model calibration performance for this population to account for the differences in the population characteristics between the combined cohorts and the original fullPIERS population as shown in Figure S3.<sup>17</sup>

The case-mix differences between our cohort and the fullPIERS cohort may have attenuated the model's

**Table 2. fullPIERS Prediction and Outcomes Rates During Admission for Preeclampsia in Data Sets**

Characteristics	BCW (218 Women)	Dutch PETRA (216 Women)	PREP (954 Women)
<b>Maternal outcome (n women)</b>			
Within 48 h of admission	23 (10.6%)	32 (14.8%)	46 (4.8%)
Within 7 d of admission	36 (16.5%)	62 (28.7%)	81 (8.5%)
At any time during admission	46 (21.1%)	73 (33.8%)	103 (10.8%)
fullPIERS probability, median (IQR)	0.0253 (0.0092, 0.0794)	0.0312 (0.0149, 0.1188)	0.0095 (0.0046, 0.0193)
fullPIERS probability mean (SD)	0.0138 (0.2104)	0.1387 (0.2390)	0.0237 (0.0664)
AUROC within 48 h of admission (95% CI)	0.729 (0.595–0.863)	0.970 (0.943–0.997)	0.730 (0.645–0.815)
Calibration slope within 48 h of admission (95% CI)	0.31 (0.21–0.41)	1.69 (1.39–1.99)	0.74 (0.63–0.86)

AUROC indicates area under the receiver operating curve; BCW, British Columbia Women; CI, confidence interval; fullPIERS, Preeclampsia Integrated Estimate of Risk; IQR, interquartile range; PETRA, Preeclampsia Eclampsia Trial Amsterdam; and PREP, Prediction of Complications in Early-Onset Preeclampsia.




**Figure 1.** Receiver operating characteristic curve for performance of the fullPIERS model (Preeclampsia Integrated Estimate of Risk) in predicting adverse maternal outcome in the early-onset preeclampsia combined cohort within 48 h of admission. PV indicates predictive value.

performance, particularly the calibration performance.<sup>17,20</sup> The most obvious case-mix difference was the selective inclusion of women with early-onset preeclampsia compared with the fullPIERS cohort that had a higher proportion of women with late-onset preeclampsia. In addition, earlier onset of preeclampsia (gestational age of onset) were associated with more adverse outcomes as shown by the overall higher rate of outcomes in this data set compared with the fullPIERS cohort. Therefore, it is possible that the predictor effect of gestational age in the fullPIERS model may have been different in our cohort compared with the fullPIERS cohort. Difference in predictor effect can affect a model's performance, especially the calibration accuracy.<sup>17,21</sup> Other contributors to case-mix differences include the addition of women admitted with severe preeclampsia as in the PETRA cohort compared with all women with preeclampsia in the model development, as well as the addition of women

admitted into both secondary and tertiary units in the PREP cohort compared with those admitted to tertiary units in the model development cohort. Another possible reason for the overall model performance reduction is the lack of spread or balance between low- and high-risk women in the combined data, that is, less heterogeneity among the women in the cohort.<sup>17</sup> Despite these known differences, our primary goal was to assess how well the model would perform in this subset of preeclampsia to determine whether it would be useful for this population.

The AUROCs in all the individual data sets were good ( $\geq 0.70$ ) although the discriminatory performance appeared to be higher in the PETRA data set, even better than the original model performance. We suspect that the inclusion of a more severe-case mix of women may have resulted in the observed higher discrimination performance. In addition, this cohort had the highest proportion of both adverse



**Figure 2.** Calibration plot of the fullPIERS model (Preeclampsia Integrated Estimate of Risk) performance in the early-onset preeclampsia combined cohort. ROC indicates receiver operating characteristic curve.

**Table 3. Risk Stratification Table to Assess the Performance of the fullPIERS Model for Predicting Maternal Outcome at Varying Predicted Probability Cutoff Values Within 48 Hours in the Early-Onset Preeclampsia Data Set**

Prediction Score Range	Total n Women in Range (%) (n=1388)	n Women With Outcome (%) (n=101)	LR [95% CI]	NPV (%) [95% CI]	PPV (%) [95% CI]	*True-Positive Rate (%) [95% CI]	False-Positive Rate (%) [95% CI]
<1.0%	594 (30.5%)	14 (1.7%)	...	...	...	...	...
1.0%–2.4%	409 (33.1%)	17 (2.8%)	0.55 [0.36–0.86]	97.6 [96.0–98.7]	11.0 [8.9–13.4]	86.1 [77.5–91.9]	54.9 [52.2–57.6]
2.5%–4.9%	158 (19.1%)	8 (4.5%)	0.68 [0.34–1.34]	96.9 [95.6–97.9]	18.2 [14.5–22.5]	69.3 [59.2–77.9]	24.5 [22.2–26.9]
5.0%–9.9%	91 (7.8%)	6 (13.7%)	0.90 [0.40–2.01]	96.6 [95.4–97.6]	27.3 [21.7–33.7]	61.4 [55.1–70.8]	12.8 [11.1–14.8]
10.0%–29.9%	68 (5.1%)	12 (15.6%)	2.73 [1.51–4.92]	95.9 [94.7–96.9]	38.5 [30.2–47.4]	49.5 [39.5–59.6]	6.2 [5.0–7.7]
≥30.0%	68 (4.4%)	44 (54.5%)	23.4 [14.83–36.79]	95.7 [94.4–96.7]	64.7 [52.1–75.6]	43.6 [33.8–53.8]	1.9 [1.3–2.8]

CI indicates confidence interval; fullPIERS, Preeclampsia Integrated Estimate of Risk; LR, likelihood ratios; NPV, negative predictive value; and PPV, positive predictive value.

\*True-positive rate (or sensitivity), false-positive rate (1-specificity).

maternal and fetal outcome, indicating a sicker group of women. However, our sensitivity analyses excluding the cases in the PETRA data did not result in a significant change in the AUROC of the model and still had good discriminatory performances for identifying women at the highest risk of maternal complications.

### Strengths and Weaknesses

An important strength in our study is the combination of cohorts from different centers which added to the robustness and generalisability of our findings. In our study, we used a data set with adequate sample which enabled us to detect any true changes in the model performance. Because we were interested in assessing the model in a general population of early-onset preeclampsia, we think that the combination of these cohorts resulted in a broader cohort of cases that could be presented to a clinician in the hospital.

Although we had a few cases of missing data, there was no significant change in the model performance results after imputation; this suggests that the point estimates obtained were less likely to be biased.<sup>17</sup>

A possible limitation in our study is that we were not able to exclude the women with only gestational hypertension and fetal growth restriction from the PETRA data because of lack of availability of information to test the model performance in the women with only early-onset preeclampsia using the exact definition as in the model development study. This may have provided information to test the proposed reasons stated above for heterogeneity case-mix in the data.

### Comparison to Existing Literature

A prediction model study (PREP model) on the prognosis of women with early-onset preeclampsia reported an AUROC of 0.84 (95% CI, 0.81–0.87) on development.<sup>15</sup> Preterm delivery was included as an adverse outcome in the study to possibly account for treatment paradox for delivery. The majority of the adverse outcomes predicted in this study by Thangaratnam et al<sup>15</sup> were preterm deliveries (61%), and no sensitivity analysis was reported for the performance of the model in predicting other adverse maternal outcomes excluding preterm delivery. In addition, observational studies have already shown that 50% of women with early-onset preeclampsia will deliver within 2 weeks and 25% within

4 weeks.<sup>22–24</sup> Therefore, it is possible that this model may not be useful for the prediction of maternal complications as iatrogenic delivery could be because of maternal or fetal indications or both. Another concern with the use of the PREP model is the inclusion of >14 variables, making it cumbersome compared with the fullPIERS model that requires only 6 variables. Model development studies have encouraged the use of a more parsimonious model because this reduces the chances of overfitting and enhances clinical utility.<sup>17</sup> Finally, the model in the study included treatment variables, such as antihypertensive and magnesium sulfate; the administration and timing of these treatments may vary based on the clinician's training and experience. Therefore, we propose that the fullPIERS model might be better for identifying women with early-onset preeclampsia at highest risk of adverse maternal outcomes, regardless of treatment. It may, however, be worthwhile to test this latter hypothesis in a similar study.

### Perspectives

The fullPIERS model was able to predict adverse maternal outcomes in women admitted with early-onset preeclampsia within 48 hours of admission and up to 7 days. Our findings could guide decision making especially the timing of delivery and planning of transfer to units for required care and administration of corticosteroid and magnesium sulfate. Thus, we think that the fullPIERS model could aid in averting severe maternal complications. We propose that women who fall in the highest risk category should be considered for delivery in settings where iatrogenic delivery can be instituted immediately and both the mother and newborn can be cared for, or at the least, close maternal and fetal surveillance. We recommend the use of the updated model (Equation 2) for management of women with early-onset preeclampsia to optimize performance. Future studies should consider dynamic modeling for risk reassessment.

### Acknowledgments

We are grateful for the contribution made by the fullPIERS (Preeclampsia Integrated Estimate of Risk), PETRA (Preeclampsia Eclampsia Trial Amsterdam), and PREP (Prediction of Complications in Early-Onset Preeclampsia) data collectors and study sites investigators who retrieved the data for this study.

## Sources of Funding

This study was supported by the Canadian Institutes of Health Research (operating grants). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

## Disclosures

None.

## References

- von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2016;36:83–102. doi: 10.1016/j.bpobgyn.2016.05.005.
- Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2011;25:391–403. doi: 10.1016/j.bpobgyn.2011.01.006.
- von Dadelszen P, Magee LA. Pre-eclampsia: an update. *Curr Hypertens Rep*. 2014;16:454. doi: 10.1007/s11906-014-0454-8.
- Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group; Canadian Hypertensive Disorders of Pregnancy HDP Working Group. The hypertensive disorders of pregnancy (29.3). *Best Pract Res Clin Obstet Gynaecol*. 2015;29:643–657. doi: 10.1016/j.bpobgyn.2015.04.001.
- Stegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet*. 2010;376:631–644. doi: 10.1016/S0140-6736(10)60279-6.
- Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. *Placenta*. 2009;30(suppl A):S38–S42. doi: 10.1016/j.placenta.2008.11.021.
- von Dadelszen P, Firoz T, Donnay F, Gordon R, Justus Hofmeyr G, Lalani S, Payne BA, Roberts JM, Teela KC, Vidler M, Sawchuck D, Magee LA. Preeclampsia in low and middle income countries—health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. *J Obstet Gynaecol Can*. 2012;34:917–926. doi: 10.1016/S1701-2163(16)35405-6.
- Payne BA, Hutcheon JA, Ansermino JM, et al; miniPIERS Study Working Group. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. *PLoS Med*. 2014;11:e1001589. doi: 10.1371/journal.pmed.1001589.
- Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. *Pregnancy Hypertens*. 2014;4:105–145. doi: 10.1016/j.preghy.2014.01.003.
- von Dadelszen P, Menzies JM, Payne B, Magee LA; PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study Group. Predicting adverse outcomes in women with severe pre-eclampsia. *Semin Perinatol*. 2009;33:152–157. doi: 10.1053/j.semperi.2009.02.009.
- von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. *Lancet*. 2011;377:219–227. doi: 10.1016/S0140-6736(10)61351-7.
- Akkermans J, Payne B, von Dadelszen P, Groen H, Vries Jd, Magee LA, Mol BW, Ganzevoort W. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. *Eur J Obstet Gynecol Reprod Biol*. 2014;179:58–62. doi: 10.1016/j.ejogrb.2014.05.021.
- Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. *J Clin Epidemiol*. 2005;58:475–483. doi: 10.1016/j.jclinepi.2004.06.017.
- Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H; PETRA- Investigators. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. *Am J Obstet Gynecol*. 2006;195:495–503. doi: 10.1016/j.ajog.2006.02.012.
- Thangaratnam S, Allotey J, Marlin N, et al. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. *BMC Med*. 2017;15:68.
- Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21:128–138. doi: 10.1097/EDE.0b013e3181c30fb2.
- Neeman T. Clinical prediction models: a practical approach to development, validation, and updating by Ewout W. Steyerberg. *Int Stat Rev*. 2009;77:320–321.
- Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. 1982;143:29–36. doi: 10.1148/radiology.143.1.7063747.
- Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. *BMJ*. 2004;329:168–169. doi: 10.1136/bmj.329.7458.168.
- Debray TP, Vergouwe Y, Koffijberg H, Nieboer D, Steyerberg EW, Moons KG. A new framework to enhance the interpretation of external validation studies of clinical prediction models. *J Clin Epidemiol*. 2015;68:279–289. doi: 10.1016/j.jclinepi.2014.06.018.
- Vergouwe Y, Moons KG, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. *Am J Epidemiol*. 2010;172:971–980. doi: 10.1093/aje/kwq223.
- Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. *Cochrane Database Syst Rev*. 2002;3:CD003106.
- Magee LA, Yong PJ, Espinosa V, Côté AM, Chen I, von Dadelszen P. Expectant management of severe preeclampsia remote from term: a structured systematic review. *Hypertens Pregnancy*. 2009;28:312–347. doi: 10.1080/10641950802601252.
- Pels A, von Dadelszen P, Engelbrecht S, Ryan H, Bellad M, Lalonde A, Magee LA. Timing and mode of delivery. In: Magee L, von Dadelszen P, Stones W, Mathai M, eds. *The FIGO Textbook of Pregnancy Hypertension an Evidence-Based Guide to Monitoring, Prevention and Management*. London, UK: The Global Library of Women's Medicine (GLOWM); 2016: 167–183.

## Novelty and Significance

### What Is New?

- We have assessed the fullPIERS model (Preeclampsia Integrated Estimate of Risk) for predicting maternal adverse outcomes from preeclampsia in women admitted with early-onset preeclampsia.
- The model has good discriminatory and stratification performances for identifying women at the highest risk of experiencing maternal complications.

### What Is Relevant?

- Early-onset preeclampsia is associated with great maternal and fetal morbidity and mortality.

- The ability to identify such women, most likely to develop adverse maternal outcomes, could aid in averting severe complications.

### Summary

This study provides evidence that the fullPIERS model can be useful in guiding the management of women admitted with early-onset preeclampsia to avoid adverse outcomes.

## Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia

U. Vivian Ukah, Beth Payne, Jennifer A. Hutcheon, J. Mark Ansermino, Wessel Ganzevoort, Shakila Thangaratinam, Laura A. Magee and Peter von Dadelszen

*Hypertension*. 2018;71:659-665; originally published online February 12, 2018;  
doi: 10.1161/HYPERTENSIONAHA.117.10318

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231  
Copyright © 2018 American Heart Association, Inc. All rights reserved.  
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://hyper.ahajournals.org/content/71/4/659>

Free via Open Access

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2018/02/06/HYPERTENSIONAHA.117.10318.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:  
<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Hypertension* is online at:  
<http://hyper.ahajournals.org/subscriptions/>



## **Assessment of the fullPIERS Risk Prediction Model in Women with Early-Onset Pre-Eclampsia**

U. Vivian Ukah, MPH<sup>1,2\*</sup>, Beth Payne, PhD<sup>2,3</sup>, Jennifer A. Hutcheon, PhD<sup>1,2</sup>, J. Mark Ansermino, MBBCh, MSc<sup>2,3</sup>, Wessel Ganzevoort, MD<sup>4</sup>, Shakila Thangaratnam, PhD, MRCOG<sup>5</sup>, Laura A. Magee, MD, MSc, FRCPC<sup>6</sup>, Peter von Dadelszen, MBChB, DPhil, FRCOG<sup>6</sup>.

### Affiliations:

1. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada
2. Healthy Starts Theme, BC Children's Hospital Research Institute, Vancouver, BC, Canada
3. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
4. Departments of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, The Netherlands
5. Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
6. School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

Address for correspondence: U. Vivian Ukah, 950 W 28th Avenue, Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC, V5Z 4H4, Canada; Telephone: +1604-875-2424 x 6112; Email: Vivian.Ukah@cw.bc.ca

Short title: Prognosis of early-onset pre-eclampsia using fullPIERS

Word Count (including references and tables): 3,300 (Abstract – 249); Total figures - 2

## S1. List and definitions of PIERS Maternal Adverse Outcomes

Outcome	Definition
Maternal Mortality	Maternal death occurring within six weeks of pregnancy or if later, attributable to complications of pre-eclampsia
Hepatic dysfunction	INR >1.2 in the absence of DIC or treatment of Warfarin (DIC is defined as having both: abnormal bleeding and consumptive coagulopathy (i.e., low platelets, abnormal peripheral blood film, or one or more of the following: increased INR, increased PTT, low fibrinogen, or increased fibrin degradation products that are outside normal non-pregnancy ranges))
Hepatic hematoma or rupture	Blood collection under the hepatic capsule as confirmed by ultrasound or laparotomy
Glasgow Coma Scale (GCS) < 13	Based on GCS scoring system: Teasdale G, Jennet B. Assessment of coma and impaired consciousness: a practical scale. <i>Lancet</i> 1974; 2:81-83
Stroke	Acute neurological event with deficits lasting longer than 48 hours
Cortical Blindness	Loss of visual acuity in the presence of intact pupillary response to light
Reversible Ischaemic Neurologic Deficit (RIND)	Cerebral ischaemia lasting longer than 24 hrs but less than 48 hours revealed through clinical examination
Retinal detachment	Separation of the inner layers of the retina from the underlying retinal pigment epithelium (RPE, choroid) and is diagnosed by ophthalmological exam
Acute renal insufficiency	For women with an underlying history of renal disease: defined as creatinine >200 uM; for patients with no underlying renal disease: defined as creatinine >150 uM
Dialysis	Including haemodialysis and peritoneal dialysis
Platelet count < 50,000 without blood transfusion	Measurement of platelet count recorded as less than 50,000 without patient being given a blood transfusion
Transfusion of blood products	Includes transfusion of any units of blood products: fresh frozen plasma (FFP), platelets, red blood cells (RBCs), cryoprecipitate (cryo) or whole blood
Positive inotropic support	The use of vasopressors to maintain a sBP > 90 mmHg or Mean Arterial pressure > 70 mmHg

Myocardial ischaemia/infarction	ECG changes (ST segment elevation or depression) without enzyme changes AND/OR any one of the following: 1)Development of new pathologic Q waves on serial ECGs. The patient may or may not remember previous symptoms. Biochemical markers of myocardial necrosis may have normalized, depending on the length of time that has passed since the infarct developed. 2) Pathological findings of an acute, healed or healing MI 3) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following: a) ischaemic symptoms; b) development of pathologic Q waves on the ECG; c) ECG changes indicative of ischaemia (ST segment elevation or depression); or d) coronary artery intervention (e.g., coronary angioplasty)
Require >50% oxygen for greater than one hour	Oxygen given at greater than 50% concentration based on local criteria for longer than 1 hour
Intubation other than for Caesarean section	Intubation may be by ventilation, EIT or CPAP
Pulmonary Oedema	Clinical diagnosis with x-ray confirmation or requirement of diuretic treatment and SaO <sub>2</sub> <95%
Eclampsia (Eclamptic seizures)	The occurrence of generalised convulsions during pregnancy, labour, or within 7 days of delivery in the absence of epilepsy or another condition predisposing to convulsions. A seizure or convulsion can be a sudden, violent, uncontrollable contraction of a group of muscles. A seizure can also be subtler, consisting of only a brief loss of contact.
Others	Bell's palsy, severe ascites, hysterectomy

S2. Adverse maternal outcomes\* in Validation datasets within 48 hrs for women admitted with pre-eclampsia (N=101 outcomes)

Events/outcomes	BCW (218 women)	Dutch PETRA (216 women)	PREP (954 women)
	Within 48h (N=23)	Within 48h (N=32)	Within 48h (N=46)
Maternal death	0	0	0
<b>CNS</b>	<b>1</b>	<b>6</b>	<b>12</b>
Eclampsia	0	3	9
Glasgow Coma <13	1	0	3
Stroke	0	0	0
TIA	0	0	0
Cortical blindness	0	0	0
Posterior reversible encephalopathy	0	2	0
<b>Cardiorespiratory</b>	<b>7</b>	<b>6</b>	<b>7</b>
Positive inotropic support	1	0	1
Infusion of a third parenteral antihypertensive drug	1	0	0
Myocardial ischaemia or infarction	0	0	0
Require O <sub>2</sub> ≥50% for >1h	4	4	1
Intubation	1	0	2
Pulmonary oedema	0	2	3
<b>Haematological</b>	<b>7</b>	<b>20</b>	<b>13</b>
Transfusion (where recorded)	4	3	7
Platelet count < 50	3	17	6
<b>Hepatic</b>	<b>1</b>	<b>0</b>	<b>0</b>
Hepatic dysfunction	1	0	0
Hepatic Rupture	0	0	0
<b>Renal</b>	<b>0</b>	<b>0</b>	<b>2</b>
Creatinine > 150 without renal disease/ Creatinine > 200 with renal disease	0	0	2
<b>Placental abruption</b>	<b>5</b>	<b>2</b>	<b>12</b>
<b>Ascites</b>	<b>1</b>	<b>0</b>	<b>0</b>
<b>Bell's Palsy</b>	<b>1</b>	<b>0</b>	<b>0</b>
<b>Hysterectomy/ruptured uterus</b>	<b>0</b>	<b>0</b>	<b>0</b>

\*First outcome occurring

S3. TRIPOD Checklist: Prediction Model Development and Validation

Section/Topic	n		Checklist Item	Page
<b>Title and abstract</b>				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	3
<b>Introduction</b>				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	4-5
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	5
<b>Methods</b>				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	6-7
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	7
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	5
	5b	D;V	Describe eligibility criteria for participants.	7
	5c	D;V	Give details of treatments received, if relevant.	n/a
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	7 & Table S1
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	n/a
Predictors	7a	D;V	Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured.	8
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	n/a
Sample size	8	D;V	Explain how the study size was arrived at.	9
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	7

Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	n/a
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	n/a
	10c	V	For validation, describe how the predictions were calculated.	8-9
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	8
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	n/a
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	8
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	6-7
<b>Results</b>				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	9-10
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	9-10
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	10/Table 1
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	n/a
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	n/a
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	n/a
	15b	D	Explain how to use the prediction model.	n/a
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	11/Table 2-3/Figures 1&2
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	n/a
<b>Discussion</b>				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	13
Interpretation	19a	V	For validation, discuss the results with reference to performance in the	11-

			development data, and any other validation data.	13
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	13-14
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	14
<b>Other information</b>				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	S1
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	16


\*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.





#### S4. STARD checklist

Section & Topic	No	Item	Reported on page #
<b>TITLE OR ABSTRACT</b>			
	<b>1</b>	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	1
<b>ABSTRACT</b>			
	<b>2</b>	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	3
<b>INTRODUCTION</b>			
	<b>3</b>	Scientific and clinical background, including the intended use and clinical role of the index test	5
	<b>4</b>	Study objectives and hypotheses	6
<b>METHODS</b>			
<i>Study design</i>	<b>5</b>	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	6
<i>Participants</i>	<b>6</b>	Eligibility criteria	7
	<b>7</b>	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	6-7
	<b>8</b>	Where and when potentially eligible participants were identified (setting, location and dates)	7
	<b>9</b>	Whether participants formed a consecutive, random or convenience series	7
<i>Test methods</i>	<b>10a</b>	Index test, in sufficient detail to allow replication	8
	<b>10b</b>	Reference standard, in sufficient detail to allow replication	8
	<b>11</b>	Rationale for choosing the reference standard (if alternatives exist)	NA
	<b>12a</b>	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	8
	<b>12b</b>	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	8
	<b>13a</b>	Whether clinical information and reference standard results were available to the performers/readers of the index test	NA
	<b>13b</b>	Whether clinical information and index test results were available to the assessors of the reference standard	NA
<i>Analysis</i>	<b>14</b>	Methods for estimating or comparing measures of diagnostic accuracy	8
	<b>15</b>	How indeterminate index test or reference standard results were handled	NA
	<b>16</b>	How missing data on the index test and reference standard were handled	9
	<b>17</b>	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	NA
	<b>18</b>	Intended sample size and how it was determined	9
<b>RESULTS</b>			
<i>Participants</i>	<b>19</b>	Flow of participants, using a diagram	NA
	<b>20</b>	Baseline demographic and clinical characteristics of participants	9-10


	<b>21a</b>	Distribution of severity of disease in those with the target condition	10
	<b>21b</b>	Distribution of alternative diagnoses in those without the target condition	NA
	<b>22</b>	Time interval and any clinical interventions between index test and reference standard	NA
<i>Test results</i>	<b>23</b>	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 3
	<b>24</b>	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Tables 2-3; Figures 1&2
	<b>25</b>	Any adverse events from performing the index test or the reference standard	NA
<b>DISCUSSION</b>			
	<b>26</b>	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	13
	<b>27</b>	Implications for practice, including the intended use and clinical role of the index test	14
<b>OTHER INFORMATION</b>			
	<b>28</b>	Registration number and name of registry	NA
	<b>29</b>	Where the full study protocol can be accessed	NA
	<b>30</b>	Sources of funding and other support; role of funders	15



**Figure S1.** Model discriminatory performance for predicting adverse maternal outcomes within 7 days of admission (AUROC 0.74 (95% CI 0.70-0.79))



**Figure S2.** Model discriminatory performance, after exclusion of the PETRA cohort, for predicting adverse maternal outcomes within (A) 48 hours (AUROC 0.74 (95% CI 0.67-0.81)) and (B) 7 days of admission (AUROC 0.70 (95% CI 0.65-0.75))



**Figure S3.** Calibration performance for updated model intercept and slope